Evidence map›Paper›PMID 34526889›Full record

ArticleFrontiers in aging neuroscience2021

The Cerebrospinal Fluid Profile of Cholesterol Metabolites in Parkinson's Disease and Their Association With Disease State and Clinical Features.

William J Griffiths, Jonas Abdel-Khalik, Sarah F Moore, Ruwani S Wijeyekoon, Peter J Crick, Eylan Yutuc, Krista Farrell, David P Breen, Caroline H Williams-Gray, Spyridon Theofilopoulos and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

William J GriffithsSwansea University Medical School, ILS1 Building, Swansea, United Kingdom.
Jonas Abdel-KhalikSwansea University Medical School, ILS1 Building, Swansea, United Kingdom.
Sarah F MooreDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
Ruwani S WijeyekoonDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
Peter J CrickSwansea University Medical School, ILS1 Building, Swansea, United Kingdom.
Eylan YutucSwansea University Medical School, ILS1 Building, Swansea, United Kingdom.
Krista FarrellDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
David P BreenCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Caroline H Williams-GrayDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
Spyridon TheofilopoulosSwansea University Medical School, ILS1 Building, Swansea, United Kingdom.
Ernest ArenasDivision of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Miles TruppDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Roger A BarkerDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
Yuqin WangSwansea University Medical School, ILS1 Building, Swansea, United Kingdom.
Swansea University · GBUniversity of Cambridge · GBKarolinska Institutet · SEUmeå University · SEUniversity of Edinburgh · GBWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Medical Research Council MC_PC_17230Medical Research Council MR/R007446/1Wellcome Trust
6 · The paper itself

Abstract

Disordered cholesterol metabolism is linked to neurodegeneration. In this study we investigated the profile of cholesterol metabolites found in the cerebrospinal fluid (CSF) of Parkinson's disease (PD) patients. When adjustments were made for confounding variables of age and sex, 7α,(25R)26-dihydroxycholesterol and a second oxysterol 7α,x,y-trihydroxycholest-4-en-3-one (7α,x,y-triHCO), whose exact structure is unknown, were found to be significantly elevated in PD CSF. The likely location of the additional hydroxy groups on the second oxysterol are on the sterol side-chain. We found that CSF 7α-hydroxycholesterol levels correlated positively with depression in PD patients, while two presumptively identified cholestenoic acids correlated negatively with depression.

Indexed as

bile acid biosynthesisdihydroxycholesterolmass spectrometryoxysterolsterol

Identifiers

PMID34526889
PMCPMC8435905
OpenAlexW3197206560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.